In real-world clinical practice, managing atopic dermatitis presents many challenges, particularly when ideal treatments are ...

Nemolizumab is safe and effective for long-term use in patients with moderate-to-severe atopic dermatitis, an extension study ...

Experts discuss the foundational role of topical therapies in pediatric atopic dermatitis management, highlighting the ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Learn the 5 key questions parents should ask about their child’s eczema treatment—including safe, steroid-free options and ...

Atopic dermatitis (the most common type of eczema) causes dry, itchy skin with rough, scaly patches. It affects up to 30% of children and 10% of adults, with about 60% of cases starting before age 1.

Please provide your email address to receive an email when new articles are posted on . Patients with atopic dermatitis that were resistant to systemic therapies, including dupilumab, were treated ...

The most common causes of an itchy scalp are dandruff, lice, psoriasis, or a stress rash. Here's how to determine which may ...

Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, ...

This approval follows the recent FDA approval of ruxolitinib cream 1.5% (Opzelura), a topical JAK inhibitor, as a treatment for mild-to-moderate AD in children ages 2-11 years, as previously reported ...

Of the children who received dupilumab, 8.9% developed ocular surface complications and 3.4% developed periocular involvement ...

Discover a study revealing how psychiatric comorbidities in people with atopic dermatitis affect mental health and quality of ...